Literature DB >> 33165734

Agomelatine confers neuroprotection against cisplatin-induced hippocampal neurotoxicity.

Fatma Nihan Cankara1, Caner Günaydın2, Zülfinaz Betül Çelik3, Yasemin Şahin4, Şakir Pekgöz4, Yalçın Erzurumlu5, Kanat Gülle6.   

Abstract

Neurotoxicity caused by cisplatin is a major obstacle during chemotherapy. Oxidative stress and inflammation are considered the primary mechanism behind neuronal damage which affects the continuing chemotherapy regimen. Agomelatine was recently described as a neuroprotective compound against toxic insults in the nervous systems. It is an analog of the well-known antioxidant and anti-inflammatory compound melatonin and currently used for depression and sleep disturbances. In the current study, we investigated the possible neuroprotective role of agomelatine against cisplatin-induced oxidative, inflammatory, and behavioral alterations in male rats. Our results show that agomelatine prevented cisplatin-induced neurotoxicity in the HT-22 mouse hippocampal neuronal cell line. Additionally, agomelatine treatment inhibited cisplatin-induced behavioral deficits and neuronal integrity in vivo. For the evaluation of the effect of agomelatine on oxidative stress and inflammation, GSH, MDA, TNF, and IL-6 levels were analyzed in HT-22 cells and hippocampal tissues. Agomelatine significantly attenuated oxidative stress and inflammation due to the cisplatin insult in vitro and in vivo. Also, agomelatine treatment ameliorated the neuronal pathology in the hippocampus, which is strongly related to cognition and memory. Taken together, our results indicate that in males, the neuroprotective effect of agomelatine is mediated through its antioxidant and anti-inflammatory actions abrogating functional deficits.

Entities:  

Keywords:  Agomelatine; Cisplatin; HT-22 cell line; Hippocampus; Neurotoxicity; Wistar-albino rat

Mesh:

Substances:

Year:  2020        PMID: 33165734     DOI: 10.1007/s11011-020-00634-y

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  22 in total

1.  A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes.

Authors:  Wendy Y Chen; Anita Giobbie-Hurder; Kathryn Gantman; Jennifer Savoie; Rochelle Scheib; Leroy M Parker; Eva S Schernhammer
Journal:  Breast Cancer Res Treat       Date:  2014-04-10       Impact factor: 4.872

2.  The effects of exogenous melatonin on peripheral nerve regeneration and collagen formation in rats.

Authors:  Bekir Atik; Ibrahim Erkutlu; Mustafa Tercan; Hakan Buyukhatipoglu; Mehmet Bekerecioglu; Sadrettin Pence
Journal:  J Surg Res       Date:  2009-07-10       Impact factor: 2.192

3.  Neuroprotection of agomelatine against cerebral ischemia/reperfusion injury through an antiapoptotic pathway in rat.

Authors:  Wijitra Chumboatong; Sarinthorn Thummayot; Piyarat Govitrapong; Chainarong Tocharus; Jinatta Jittiwat; Jiraporn Tocharus
Journal:  Neurochem Int       Date:  2016-12-22       Impact factor: 3.921

4.  Effect of subchronic administration of agomelatine on brain energy metabolism and oxidative stress parameters in rats.

Authors:  Aline Haas de Mello; Luana da Rosa Souza; Ana Carla Moreira Cereja; Rosiane de Bona Schraiber; Drielly Florentino; Maryane Modolon Martins; Fabricia Petronilho; João Quevedo; Gislaine Tezza Rezin
Journal:  Psychiatry Clin Neurosci       Date:  2015-12-22       Impact factor: 5.188

5.  The preventive effect of oxytocin to Cisplatin-induced neurotoxicity: an experimental rat model.

Authors:  Tulay Akman; Levent Akman; Oytun Erbas; Mustafa Cosan Terek; Dilek Taskiran; Aydin Ozsaran
Journal:  Biomed Res Int       Date:  2015-01-22       Impact factor: 3.411

6.  Brain-derived neurotrophic factor and its clinical implications.

Authors:  Siresha Bathina; Undurti N Das
Journal:  Arch Med Sci       Date:  2015-12-11       Impact factor: 3.318

Review 7.  Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.

Authors:  Andrea Cipriani; Toshi A Furukawa; Georgia Salanti; Anna Chaimani; Lauren Z Atkinson; Yusuke Ogawa; Stefan Leucht; Henricus G Ruhe; Erick H Turner; Julian P T Higgins; Matthias Egger; Nozomi Takeshima; Yu Hayasaka; Hissei Imai; Kiyomi Shinohara; Aran Tajika; John P A Ioannidis; John R Geddes
Journal:  Lancet       Date:  2018-02-21       Impact factor: 79.321

8.  Neuroprotective effect of N-acetylcysteine against cisplatin-induced toxicity in rat brain by modulation of oxidative stress and inflammation.

Authors:  Wessam M Abdel-Wahab; Farouzia I Moussa
Journal:  Drug Des Devel Ther       Date:  2019-04-11       Impact factor: 4.162

9.  Successful use of agomelatine in the treatment of major depression in a woman taking tamoxifen: a case report.

Authors:  Domenico De Berardis; Maurizio Brucchi; Nicola Serroni; Alessandro Valchera; Michele Fornaro; Monica Mazza; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Clin Neuropharmacol       Date:  2014 Jan-Feb       Impact factor: 1.592

10.  Effects of agomelatine on oxidative stress in the brain of mice after chemically induced seizures.

Authors:  Carlos Clayton Torres Aguiar; Anália Barbosa Almeida; Paulo Victor Pontes Araújo; Germana Silva Vasconcelos; Edna Maria Camelo Chaves; Otoni Cardoso do Vale; Danielle Silveira Macêdo; Luzia Kalyne Almeida Moreira Leal; Glauce Socorro de Barros Viana; Silvânia Maria Mendes Vasconcelos
Journal:  Cell Mol Neurobiol       Date:  2013-06-26       Impact factor: 5.046

View more
  3 in total

1.  Metabolic Impact of Anticancer Drugs Pd2Spermine and Cisplatin on the Brain of Healthy Mice.

Authors:  Tatiana J Carneiro; Martin Vojtek; Salomé Gonçalves-Monteiro; João R Neves; Ana L M Batista de Carvalho; Maria Paula M Marques; Carmen Diniz; Ana M Gil
Journal:  Pharmaceutics       Date:  2022-01-22       Impact factor: 6.321

2.  Brain Protection by Methylene Blue and Its Derivative, Azur B, via Activation of the Nrf2/ARE Pathway in Cisplatin-Induced Cognitive Impairment.

Authors:  Ekaterina P Krutskikh; Daria V Potanina; Natalia A Samoylova; Mariya V Gryaznova; Irina S Sadovnikova; Artem P Gureev; Vasily N Popov
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-30

3.  Neuroprotective Potential of Bone Marrow-Derived Mesenchymal Stem Cells Following Chemotherapy.

Authors:  Iman O Sherif; Nora H Al-Shaalan; Dina Sabry
Journal:  Biomedicines       Date:  2021-06-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.